Menu Search
Equities

Eden Research PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9T7:STU

Eden Research PLC

Actions
  • Price (EUR)0.0275
  • Today's Change-0.001 / -1.79%
  • Shares traded0.00
  • 1 Year change-38.89%
  • Beta1.4159
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Eden Research plc is a United Kingdom-based company, which is focused on biopesticides for sustainable agriculture. The Company develops and supplies biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Its products include crop protection, animal health, and consumer products. Its crop protection includes Mevalone and Cedroz. Mevalone is a foliar, contact biofungicide which delivers a controlled release pattern of multiple terpene active ingredients. Cedroz is a terpene-based product developed in conjunction with Eastman Chemical Company as a post-planting solution to the problem of root-knot nematodes. The Company's Sustaine encapsulation technology is used to harness the biocidal activity of naturally occurring molecules produced by plants (terpenes) as part of their defence systems. Sustaine is used in a wide range of applications such as agricultural, animal health and consumer products

  • Revenue in GBP (TTM)3.62m
  • Net income in GBP-2.35m
  • Incorporated1995
  • Employees23.00
  • Location
    Eden Research PLC67C Innovation Drive, Milton ParkOXFORD OX14 4RQUnited KingdomGBR
  • Phone+44 128 535 9555
  • Fax+44 199 377 6480
  • Websitehttps://www.edenresearch.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.